A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
07
03
2023
accepted:
27
11
2023
medline:
6
1
2024
pubmed:
6
1
2024
entrez:
5
1
2024
Statut:
epublish
Résumé
Malignant melanoma is the most aggressive and deadly skin cancer with an increasing incidence worldwide whereas SCC is the second most common non-melanoma human skin cancer with limited treatment options. Here we show that the development and metastasis of melanoma and SCC cancers can be blocked by a combined opposite targeting of RhoA and p110δ PI3K. We found that a targeted induction of RhoA activity into tumours by deletion of p190RhoGAP-a potent inhibitor of RhoA GTPase-in tumour cells together with adoptive macrophages transfer from δ
Identifiants
pubmed: 38182748
doi: 10.1038/s42003-023-05639-8
pii: 10.1038/s42003-023-05639-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Informations de copyright
© 2024. The Author(s).
Références
Zhang, W. et al. Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Cancer Med. 10, 4905–4922 (2021).
pubmed: 34105887
pmcid: 8290243
doi: 10.1002/cam4.4046
Steininger, J. et al. Systemic therapy of metastatic melanoma: on the road to cure. Cancers 13, 1430. https://doi.org/10.3390/cancers13061430 (2021).
Chong, C. Y., Goh, M. S., Porceddu, S. V., Rischin, D. & Lim, A. M. The current treatment landscape of cutaneous squamous cell carcinoma. Am. J. Clin. Dermatol. https://doi.org/10.1007/s40257-022-00742-8 (2022).
Boukamp, P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 26, 1657–1667 (2005).
pubmed: 15905207
doi: 10.1093/carcin/bgi123
Garcia-Foncillas, J. et al. Update on management recommendations for advanced cutaneous squamous cell carcinoma. Cancers 14, 629. https://doi.org/10.3390/cancers14030629 (2022).
Neagu, M., Constantin, C., Manda, G. & Margaritescu, I. Biomarkers of metastatic melanoma. Biomark. Med. 3, 71–89 (2009).
pubmed: 20477497
doi: 10.2217/17520363.3.1.71
Neagu, M. The immune system—a hidden treasure for biomarker discovery in cutaneous melanoma. Adv. Clin. Chem. 58, 89–140 (2012).
pubmed: 22950344
doi: 10.1016/B978-0-12-394383-5.00011-4
Barrio, M. M. et al. Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells. PLoS One 7, e40311 (2012).
pubmed: 22768350
pmcid: 3388056
doi: 10.1371/journal.pone.0040311
Bröcker, E. B., Zwadlo, G., Holzmann, B., Macher, E. & Sorg, C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int. J. Cancer 41, 562–567 (1988).
pubmed: 3128489
doi: 10.1002/ijc.2910410415
Fujimura, T., Kakizaki, A., Furudate, S., Kambayashi, Y. & Aiba, S. Tumor-associated macrophages in skin: how to treat their heterogeneity and plasticity. J. Dermatol. Sci. 83, 167–173 (2016).
pubmed: 27291068
doi: 10.1016/j.jdermsci.2016.05.015
Falleni, M. et al. M1 and M2 macrophages’ clinicopathological significance in cutaneous melanoma. Melanoma Res. 27, 00–210 (2017).
doi: 10.1097/CMR.0000000000000352
Heppt, M. V. & Leiter, U. Cutaneous squamous cell carcinoma: state of the art, perspectives and unmet needs. J. Dtsch Dermatol Ges. 21, 421–424 (2023).
pubmed: 37070515
Zilberg, C., Lyons, J. G., Gupta, R., Ferguson, A. & Damian, D. L. The tumor immune microenvironment in cutaneous squamous cell carcinoma arising in organ transplant recipients. Ann. Dermatol. 35, 91–99 (2023).
pubmed: 37041702
pmcid: 10112371
doi: 10.5021/ad.22.175
Krynitz, B. et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—a Swedish population-based study. Int. J. Cancer 132, 1429–1438 (2013).
pubmed: 22886725
doi: 10.1002/ijc.27765
Wehner, M. R. et al. Risks of multiple skin cancers in organ transplant recipients: a cohort study in 2 administrative data sets. JAMA Dermatol. 157, 1447–1455 (2021).
pubmed: 34668933
doi: 10.1001/jamadermatol.2021.4148
Cyrus, N. et al. Density and polarization states of tumor-associated macrophages in human cutaneous squamous cell carcinomas arising in solid organ transplant recipients. Dermatol. Surg. 42, S18–S23 (2016).
pubmed: 26035047
doi: 10.1097/DSS.0000000000000371
Nam, S. W. et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61, 6938–6944 (2001).
pubmed: 11559573
Stracke, M. L. et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524–2529 (1992).
pubmed: 1733949
doi: 10.1016/S0021-9258(18)45911-X
Perrakis, A. & Moolenaar, W. H. Autotaxin: structure-function and signaling. J. Lipid Res. 55, 1010–1018 (2014).
pubmed: 24548887
pmcid: 4031933
doi: 10.1194/jlr.R046391
Tokumura, A. et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436–39442 (2002).
pubmed: 12176993
doi: 10.1074/jbc.M205623200
Umezu-Goto, M. et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227–233 (2002).
pubmed: 12119361
pmcid: 2173129
doi: 10.1083/jcb.200204026
Benesch, M. G. K., Tang, X. & Brindley, D. N. Autotaxin and breast cancer: towards overcoming treatment barriers and sequelae. Cancers 12, https://doi.org/10.3390/cancers12020374 (2020).
Ninou, I., Magkrioti, C. & Aidinis, V. Autotaxin in pathophysiology and pulmonary fibrosis. Front. Med. 5, 180 (2018).
doi: 10.3389/fmed.2018.00180
Tang, X., Benesch, M. G. K. & Brindley, D. N. Role of the autotaxin-lysophosphatidate axis in the development of resistance to cancer therapy. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865, 158716 (2020).
pubmed: 32305571
doi: 10.1016/j.bbalip.2020.158716
Benesch, M. G., Ko, Y. M., McMullen, T. P. & Brindley, D. N. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 588, 2712–2727 (2014).
pubmed: 24560789
doi: 10.1016/j.febslet.2014.02.009
Samadi, N. et al. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 93, 61–70 (2011).
pubmed: 20709140
doi: 10.1016/j.biochi.2010.08.002
Tang, X. et al. Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer. Mol. Cancer Ther. 19, 63–74 (2020).
pubmed: 31548293
doi: 10.1158/1535-7163.MCT-19-0386
Auciello, F. R. et al. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discov. 9, 617–627 (2019).
pubmed: 30837243
pmcid: 6497553
doi: 10.1158/2159-8290.CD-18-1212
David, M. et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 5, e9741 (2010).
pubmed: 20305819
pmcid: 2840030
doi: 10.1371/journal.pone.0009741
Lin, S. et al. Autotaxin determines colitis severity in mice and is secreted by B cells in the colon. FASEB J. 33, 3623–3635 (2019).
pubmed: 30481488
doi: 10.1096/fj.201801415RR
Liu, S. et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15, 539–550 (2009).
pubmed: 19477432
pmcid: 4157573
doi: 10.1016/j.ccr.2009.03.027
Marshall, J. C. et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J. Natl. Cancer Inst. 104, 1306–1319 (2012).
pubmed: 22911670
pmcid: 3611817
doi: 10.1093/jnci/djs319
Benesch, M. G. K., MacIntyre, I. T. K., McMullen, T. P. W. & Brindley, D. N. Coming of age for autotaxin and lysophosphatidate signaling: clinical applications for preventing, detecting and targeting tumor-promoting inflammation. Cancers 10, https://doi.org/10.3390/cancers10030073 (2018).
Mills, G. B. & Moolenaar, W. H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3, 582–591 (2003).
pubmed: 12894246
doi: 10.1038/nrc1143
Aiello, S. & Casiraghi, F. Lysophosphatidic acid: promoter of cancer progression and of tumor microenvironment development. a promising target for anticancer therapies? Cells 10, https://doi.org/10.3390/cells100613901390 (2021).
Reinartz, S. et al. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment. Mol. Oncol. 13, 185–201 (2019).
pubmed: 30353652
doi: 10.1002/1878-0261.12396
Germano, G. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249–262 (2013).
pubmed: 23410977
doi: 10.1016/j.ccr.2013.01.008
Ries, C. H. et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859 (2014).
pubmed: 24898549
doi: 10.1016/j.ccr.2014.05.016
Leo, M. S. & Sivamani, R. K. Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease. Arch. Dermatol. Res. 306, 861–871 (2014).
pubmed: 24972910
doi: 10.1007/s00403-014-1480-8
Populo, H., Soares, P. & Lopes, J. M. Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin. Ther. Targets 16, 689–705 (2012).
pubmed: 22620498
doi: 10.1517/14728222.2012.691472
Populo, H., Lopes, J. M. & Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 13, 1886–1918 (2012).
pubmed: 22408430
pmcid: 3291999
doi: 10.3390/ijms13021886
Tran, K. B. et al. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK. BMC Cancer 21, 136 (2021).
pubmed: 33549048
pmcid: 7866738
doi: 10.1186/s12885-021-07826-4
Teng, Y. et al. The PI3K/Akt pathway: emerging roles in skin homeostasis and a group of non-malignant skin disorders. Cells 10, https://doi.org/10.3390/cells10051219 (2021).
Kwong, L. N. & Davies, M. A. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin. Cancer Res. 19, 5310–5319 (2013).
pubmed: 24089444
doi: 10.1158/1078-0432.CCR-13-0142
Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80–93 (2014).
pubmed: 24265155
doi: 10.1158/2159-8290.CD-13-0642
Romano, G. et al. A preexisting rare PIK3CA(E545K) subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov. 8, 556–567 (2018).
pubmed: 29496665
pmcid: 5932238
doi: 10.1158/2159-8290.CD-17-0745
Chi, M., Ye, Y., Zhang, X. D. & Chen, J. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des., Dev. Ther. 8, 255–262 (2014).
Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94–109 (2014).
pubmed: 24265153
doi: 10.1158/2159-8290.CD-13-0617
Hilke, F. J. et al. Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients. Cancers 12, https://doi.org/10.3390/cancers120923592359cancers12092359 (2020).
Trujillo, J. A. et al. Secondary resistance to immunotherapy associated with beta-catenin pathway activation or PTEN loss in metastatic melanoma. J. Immunother. Cancer 7, 295 (2019).
pubmed: 31703593
pmcid: 6839232
doi: 10.1186/s40425-019-0780-0
Chen, S. J. et al. Stromal cell-derived factor 1 expression in various skin tumours. Br. J. Dermatol 160, 710–713 (2009).
pubmed: 19183177
doi: 10.1111/j.1365-2133.2008.08996.x
Massarelli, E. et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 26, 1476–1480 (2015).
pubmed: 26025965
pmcid: 4855241
doi: 10.1093/annonc/mdv194
Schadendorf, D. et al. Melanoma. Lancet 392, 971–984 (2018). [pii]10.1016/S0140-6736(18)31559-9.
pubmed: 30238891
doi: 10.1016/S0140-6736(18)31559-9
Lim, S. Y., Menzies, A. M. & Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 123, 2118–2129 (2017).
pubmed: 28543695
doi: 10.1002/cncr.30435
Kakadia, S. et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 11, 7095–7107 (2018).
pubmed: 30410366
pmcid: 6200076
doi: 10.2147/OTT.S182721
Tran, K. B., Buchanan, C. M. & Shepherd, P. R. Evolution of molecular targets in melanoma treatment. Curr. Pharm. Des. 26, 396–414 (2020).
pubmed: 32000640
doi: 10.2174/1381612826666200130091318
Deuker, M. M., Marsh Durban, V., Phillips, W. A. & McMahon, M. PI3’-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov. 5, 143–153 (2015).
pubmed: 25472943
doi: 10.1158/2159-8290.CD-14-0856
Deuker, M. M. & McMahon, M. Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy. Mol. Cell Oncol. 3, e1033095 (2016).
pubmed: 27314067
doi: 10.1080/23723556.2015.1033095
Marsh Durban, V., Deuker, M. M., Bosenberg, M. W., Phillips, W. & McMahon, M. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J. Clin. Investig. 123, 5104–5118 (2013).
pubmed: 24200692
pmcid: 3859393
doi: 10.1172/JCI69619
Sweetlove, M. et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front Oncol. 5, 135 (2015).
pubmed: 26137449
pmcid: 4468830
doi: 10.3389/fonc.2015.00135
Chamcheu, J. C. et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells 8, https://doi.org/10.3390/cells8080803803cells8080803 (2019).
Vanhaesebroeck, B., Leevers, S. J., Panayotou, G. & Waterfield, M. D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22, 267–272 (1997).
pubmed: 9255069
doi: 10.1016/S0968-0004(97)01061-X
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329–341 (2010).
pubmed: 20379207
doi: 10.1038/nrm2882
Vanhaesebroeck, B., Whitehead, M. A. & Pineiro, R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J. Mol. Med. 94, 5–11 (2016).
pubmed: 26658520
doi: 10.1007/s00109-015-1352-5
Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110a subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963–10968 (1999).
pubmed: 10196176
doi: 10.1074/jbc.274.16.10963
Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI 3-kinase. Mamm. Genome 13, 169–172 (2002).
pubmed: 11919689
Geering, B. et al. phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. USA 104, 7809–7814 (2007).
pubmed: 17470792
pmcid: 1876529
doi: 10.1073/pnas.0700373104
Hu, P., Mondino, A., Skolnik, E. Y. & Schlessinger, J. Cloning of a novel ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13, 7677–7688 (1993).
pubmed: 8246984
pmcid: 364839
Vanhaesebroeck, B. et al. p110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl Acad. Sci. USA 94, 4330–4335 (1997).
pubmed: 9113989
pmcid: 20722
doi: 10.1073/pnas.94.9.4330
Chantry, D. et al. p110delta a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 272, 19236–19241 (1997).
pubmed: 9235916
doi: 10.1074/jbc.272.31.19236
Sawyer, C. et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res. 63, 1667–1675 (2003).
pubmed: 12670921
Tzenaki, N. et al. High levels of p110d PI3K expression in solid tumor cells suppresses PTEN activity, generating cellular sensitivity to p110d inhibitors through PTEN activation. FASEB J. 26, 2498–2508 (2012).
pubmed: 22391131
doi: 10.1096/fj.11-198192
Goulielmaki, E. et al. Pharmacological inactivation of the PI3K p110delta prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death Dis. 9, 678 (2018).
pubmed: 29880805
pmcid: 5992183
doi: 10.1038/s41419-018-0717-4
Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
pubmed: 18772396
pmcid: 2820389
doi: 10.1126/science.1164382
Samuels, Y. & Velculescu, V. E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221–1224 (2004).
pubmed: 15467468
doi: 10.4161/cc.3.10.1164
TGCA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
doi: 10.1038/nature07385
Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347–351 (2007).
pubmed: 17293865
doi: 10.1038/ng1975
Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
pubmed: 17932254
doi: 10.1126/science.1145720
Angulo, I. et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 342, 866–871 (2013).
pubmed: 24136356
pmcid: 3930011
doi: 10.1126/science.1243292
Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88–97 (2014).
pubmed: 24165795
doi: 10.1038/ni.2771
Coulter, T. I. et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J. Allergy Clin. Immunol. 139, 597–606.e594 (2017).
pubmed: 27555459
pmcid: 5292996
doi: 10.1016/j.jaci.2016.06.021
Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 1398–1403 (2013).
pubmed: 23292937
pmcid: 3557051
doi: 10.1073/pnas.1205299110
Xenou, L. & Papakonstanti, E. A. p110delta PI3K as a therapeutic target of solid tumours. Clin. Sci. 134, 1377–1397 (2020).
doi: 10.1042/CS20190772
Ko, E. et al. PI3Kdelta is a therapeutic target in hepatocellular carcinoma. Hepatology 68, 2285–2300 (2018).
pubmed: 30300952
doi: 10.1002/hep.30307
Klarlund, J. et al. Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science 275, 1927–1930 (1997).
pubmed: 9072969
doi: 10.1126/science.275.5308.1927
Welch, H. C. et al. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108, 809–821 (2002).
pubmed: 11955434
doi: 10.1016/S0092-8674(02)00663-3
Krugmann, S., Cooper, M. A., Williams, D. H., Hawkins, P. T. & Stephens, L. R. Mechanism of the regulation of type IB phosphoinositide 3OH-kinase by G-protein bg subunits. Biochem. J. 362, 725–731 (2002).
pubmed: 11879201
pmcid: 1222438
doi: 10.1042/bj3620725
Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M. P. Targeting phosphoinositide 3-kinaseβ€”Moving towards therapy. Biochim Biophys. Acta 1784, 159–185 (2008).
pubmed: 17997386
doi: 10.1016/j.bbapap.2007.10.003
Bernards, A. & Settleman, J. GAPs in growth factor signalling. Growth Factors 23, 143–149 (2005).
pubmed: 16019436
doi: 10.1080/08977190500130480
Bermudez Brito, M., Goulielmaki, E. & Papakonstanti, E. A. Focus on PTEN regulation. Front. Oncol. 5, 166 (2015).
pubmed: 26284192
pmcid: 4515857
doi: 10.3389/fonc.2015.00166
Papakonstanti, E. A., Ridley, A. J. & Vanhaesebroeck, B. The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J. 26, 3050–3061 (2007).
pubmed: 17581634
pmcid: 1914109
doi: 10.1038/sj.emboj.7601763
Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110d PI 3-kinase mutant mice. Science 297, 1031–1034 (2002).
pubmed: 12130661
doi: 10.1126/science.1073560
Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G. & Staunton, D. E. Essential role of phosphoinositide 3-Kinase d in neutrophil directional movement. J. Immunol. 170, 2647–2654 (2003).
pubmed: 12594293
doi: 10.4049/jimmunol.170.5.2647
Li, Z. et al. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 7, 399–404 (2005).
pubmed: 15793569
doi: 10.1038/ncb1236
Sanchez, T. et al. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 102, 4312–4317 (2005).
pubmed: 15764699
pmcid: 555509
doi: 10.1073/pnas.0409784102
Levay, M., Bartos, B. & Ligeti, E. p190RhoGAP has cellular RacGAP activity regulated by a polybasic region. Cell Signal 25, 1388–1394 (2013).
pubmed: 23499677
doi: 10.1016/j.cellsig.2013.03.004
Xue, C. et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res. 66, 192–197 (2006).
pubmed: 16397232
doi: 10.1158/0008-5472.CAN-05-1242
Gilles, C. et al. Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Res. 63, 2658–2664 (2003).
pubmed: 12750294
Korsching, E. et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J. Pathol. 206, 451–457 (2005).
pubmed: 15906273
doi: 10.1002/path.1797
Melnikova, V. O., Bolshakov, S. V., Walker, C. & Ananthaswamy, H. N. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23, 2347–2356 (2004).
pubmed: 14743208
doi: 10.1038/sj.onc.1207405
Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).
pubmed: 22554099
pmcid: 3391993
doi: 10.1186/1479-5876-10-85
Lee, S. C. et al. Regulation of tumor immunity by lysophosphatidic acid. Cancers 12, https://doi.org/10.3390/cancers120512021202cancers12051202 (2020).
Riento, K. & Ridley, A. J. ROCKS: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4, 446–456 (2003).
pubmed: 12778124
doi: 10.1038/nrm1128
Rosivatz, E. et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem. Biol. 1, 780–790 (2007).
doi: 10.1021/cb600352f
Gierse, J. et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J. Pharm. Exp. Ther. 334, 310–317 (2010).
doi: 10.1124/jpet.110.165845
Katsifa, A. et al. The bulk of autotaxin activity is dispensable for adult mouse life. PLoS One 10, e0143083 (2015).
pubmed: 26569406
pmcid: 4646642
doi: 10.1371/journal.pone.0143083
Cao, P. et al. Autocrine lysophosphatidic acid signaling activates beta-catenin and promotes lung allograft fibrosis. J. Clin. Investig. 127, 1517–1530 (2017).
pubmed: 28240604
pmcid: 5373892
doi: 10.1172/JCI88896
Ascierto, P. A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31, 3205–3211 (2013).
pubmed: 23918947
doi: 10.1200/JCO.2013.49.8691
Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010).
pubmed: 21107323
pmcid: 3143360
doi: 10.1038/nature09626
Sullivan, R. J. & Flaherty, K. T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49, 1297–1304 (2013).
pubmed: 23290787
doi: 10.1016/j.ejca.2012.11.019
Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014).
pubmed: 25265492
doi: 10.1056/NEJMoa1406037
Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39 (2015).
pubmed: 25399551
doi: 10.1056/NEJMoa1412690
Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–1876 (2014).
pubmed: 25265494
doi: 10.1056/NEJMoa1408868
Tolcher, A. W., Peng, W. & Calvo, E. Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors. Mol. Cancer Ther. 17, 3–16 (2018).
pubmed: 29295962
doi: 10.1158/1535-7163.MCT-17-0349
Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010).
pubmed: 21156289
pmcid: 3026446
doi: 10.1016/j.ccr.2010.11.023
Scott, J., Rees, L., Gallimore, A. & Lauder, S. N. PI3K isoform immunotherapy for solid tumours. Curr. Top. Microbiol. Immunol. 436, 369–392 (2022).
pubmed: 36243853
Yang, D. et al. Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization. Mol. Cell Biochem. 477, 2469–2480 (2022).
pubmed: 35590082
doi: 10.1007/s11010-022-04461-w
Cheng, Y. et al. Phosphoinositide-binding protein TIPE1 promotes alternative activation of macrophages and tumor progression via PIP3/Akt/TGFbeta axis. Cancer Res. 82, 1603–1616 (2022).
pubmed: 35135809
doi: 10.1158/0008-5472.CAN-21-0003
Li, Y. et al. Functional and therapeutic significance of tumor-associated macrophages in colorectal cancer. Front. Oncol. 12, 781233 (2022).
pubmed: 35186730
pmcid: 8847181
doi: 10.3389/fonc.2022.781233
Khan, M. W. et al. PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer. Clin. Cancer Res. 19, 2342–2354 (2013).
pubmed: 23487439
pmcid: 3947836
doi: 10.1158/1078-0432.CCR-12-2623
Le, F. et al. TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-kappaB-signaling pathway to inhibit the polarization of M2 TAMs. Front. Oncol. 11, 704001 (2021).
pubmed: 34381726
pmcid: 8350572
doi: 10.3389/fonc.2021.704001
Niu, X. et al. Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization. Cell Death Dis. 12, 509 (2021).
pubmed: 34006822
pmcid: 8131586
doi: 10.1038/s41419-021-03781-x
Peng, X. H. et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem. 281, 25903–25914 (2006).
pubmed: 16847054
doi: 10.1074/jbc.M603414200
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).
pubmed: 23550210
pmcid: 4160307
doi: 10.1126/scisignal.2004088
Brindley, D. N., Tang, X., Meng, G. & Benesch, M. G. K. Role of adipose tissue-derived autotaxin, lysophosphatidate signaling, and inflammation in the progression and treatment of breast cancer. Int. J. Mol. Sci. 21, https://doi.org/10.3390/ijms211659385938ijms21165938 (2020).
van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T. & Moolenaar, W. H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59, 45–54 (1989).
pubmed: 2551506
doi: 10.1016/0092-8674(89)90868-4
Jongsma, M., Matas-Rico, E., Rzadkowski, A., Jalink, K. & Moolenaar, W. H. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS One 6, e29260 (2011).
pubmed: 22195035
pmcid: 3237609
doi: 10.1371/journal.pone.0029260
Lee, S. C. et al. Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol. Cancer Res. 13, 174–185 (2015).
pubmed: 25158955
doi: 10.1158/1541-7786.MCR-14-0263
Oda, S. K. et al. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol. Res. 1, 245–255 (2013).
pubmed: 24455753
pmcid: 3893823
doi: 10.1158/2326-6066.CIR-13-0043-T
Altman, M. K. et al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol. Cancer 9, 140 (2010).
pubmed: 20529378
pmcid: 2895597
doi: 10.1186/1476-4598-9-140
Gaetano, C. G. et al. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol. Carcinog. 48, 801–809 (2009).
pubmed: 19204929
pmcid: 2736327
doi: 10.1002/mc.20524
Cha, Y. J. & Koo, J. S. Expression of autotaxin(-)lysophosphatidate signaling-related proteins in breast cancer with adipose stroma. Int. J. Mol. Sci. 20, https://doi.org/10.3390/ijms20092102 (2019).
Benesch, M. G. et al. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 28, 2655–2666 (2014).
pubmed: 24599971
doi: 10.1096/fj.13-248641
Langedijk, J. et al. Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166239, https://doi.org/10.1016/j.bbadis.2021.166239 (2021).
Zhang, X., Li, M., Yin, N. & Zhang, J. The expression regulation and biological function of autotaxin. Cells 10, https://doi.org/10.3390/cells10040939939cells10040939 (2021).
Lyu, L., Wang, B., Xiong, C., Zhang, X. & Zhang, J. Selective export of autotaxin from the endoplasmic reticulum. J. Biol. Chem. 292, 7011–7022 (2017).
pubmed: 28298439
pmcid: 5409469
doi: 10.1074/jbc.M116.774356
Cao, P. et al. Loss of FOXF1 expression promotes human lung-resident mesenchymal stromal cell migration via ATX/LPA/LPA1 signaling axis. Sci. Rep. 10, 21231 (2020).
pubmed: 33277571
pmcid: 7718269
doi: 10.1038/s41598-020-77601-1
Bellenghi, M. et al. Sex and gender disparities in melanoma. Cancers 12, https://doi.org/10.3390/cancers120718191819cancers12071819 (2020).
Gupta, S., Artomov, M., Goggins, W., Daly, M. & Tsao, H. Gender Disparity and Mutation Burden in Metastatic Melanoma. J. Natl. Cancer Inst. 107 (2015).
Anzai, K. et al. Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo. Cancer Sci. 102, 1176–1180 (2011).
pubmed: 21352422
doi: 10.1111/j.1349-7006.2011.01916.x
Gao, M. et al. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Br. J. Cancer 120, 88–96 (2019).
pubmed: 30377341
doi: 10.1038/s41416-018-0298-0
Bjorge, J. D. et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS One 6, e19309 (2011).
pubmed: 21541295
pmcid: 3082570
doi: 10.1371/journal.pone.0019309
Xiong, W. et al. Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J. Biol. Chem. 284, 1765–1771 (2009).
pubmed: 19010778
pmcid: 2615502
doi: 10.1074/jbc.M806239200
Tang, X., Wang, X., Zhao, Y. Y., Curtis, J. M. & Brindley, D. N. Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-kappaB activation. Mol. Cancer 16, 36 (2017).
pubmed: 28178994
pmcid: 5299726
doi: 10.1186/s12943-017-0607-x
Robertson, D., Savage, K., Reis-Filho, J. & Isacke, C. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 9, 13 (2008).
pubmed: 18366689
pmcid: 2288605
doi: 10.1186/1471-2121-9-13
Prasad, K. & Prabhu, G. K. Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research–a review. J. Med. Syst. 36, 2621–2631 (2012).
pubmed: 21584771
doi: 10.1007/s10916-011-9737-7
Sun, L., Han, X. & Egeblad, M. Isolation of mouse mammary carcinoma-derived macrophages and cancer cells for co-culture assays. STAR Protoc. 3, 101833 (2022).
pubmed: 36386879
pmcid: 9664409
doi: 10.1016/j.xpro.2022.101833